From Medscape Oncology

Gastrointestinal Cancers Symposium (GICS) 2019

January 17 - 19, 2019; San Francisco, California

January 17 - 19, 2019 San Francisco, California

GICS 2019 'Impressive' Activity with BRAF/MEK Inhibitors in Biliary Cancer Combination therapy with dabrafenib and trametinib produced promising results in patients with advanced BRAF V600E-mutated biliary cancers.
Medscape Medical News, January 24, 2019
GICS 2019 Survival Benefit With Combo Immunotherapy in Advanced CRC Combined durvalumab and tremelimumab improved overall survival in patients with advanced refractory colorectal cancer who were unselected for mismatch repair deficiency.
Medscape Medical News, January 23, 2019
GICS 2019 New Standard of Care in PD-L1+ Esophageal Cancer? Patients with advanced esophageal cancer who have a high level of PD-L1 showed improved survival on poembrolizumab compared to standard chemotherapy.
Medscape Medical News, January 21, 2019

GICS 2019 MMP9 Inhibitor Added to Chemo in Gastric/GEJ Cancer
Medscape Medical News, January 21, 2019
GICS 2019 New Standard of Care in PD-L1+ Esophageal Cancer?
Medscape Medical News, January 21, 2019